Novo Nordisk A/S (NOVO-B.CO)
Novo Nordisk A/S engages in the research, development, manufacture, and distribution of pharmaceutical products, primarily focusing on diabetes and obesity care, as well as rare diseases. The company also provides innovative treatment solutions, including smart insulin pens and applications for insulin dose guidance.
Company Info
Highlights
DKK 2.61T
DKK 22.65
26.38
1.19
DKK 290.40B
DKK 245.88B
DKK 108.58B
DKK 526.00 - DKK 1,029.23
DKK 813.17
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of DKK 10,000 in Novo Nordisk A/S, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Novo Nordisk A/S had a return of -4.63% year-to-date (YTD) and -27.55% in the last 12 months. Over the past 10 years, Novo Nordisk A/S had an annualized return of 16.89%, outperforming the S&P 500 benchmark which had an annualized return of 11.26%.
NOVO-B.CO
-4.63%
3.78%
-35.40%
-27.55%
24.51%
16.89%
^GSPC (Benchmark)
4.01%
1.13%
9.82%
22.80%
12.93%
11.26%
Monthly Returns
The table below presents the monthly returns of NOVO-B.CO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -2.71% | -4.63% | |||||||||||
| 2024 | 10.99% | 5.80% | 8.29% | 2.42% | 2.74% | 8.44% | -9.31% | 3.26% | -16.13% | -3.01% | -0.76% | -17.58% | -9.59% |
| 2023 | 0.53% | 5.64% | 9.86% | 3.57% | -0.75% | -1.51% | -0.65% | 17.20% | 1.08% | 5.14% | 2.73% | 0.37% | 50.74% |
| 2022 | -10.73% | 3.96% | 10.84% | 8.47% | -5.49% | 2.54% | 8.49% | -5.66% | -3.92% | 7.58% | 7.92% | 6.11% | 30.98% |
| 2021 | -0.29% | 2.95% | -0.50% | 5.42% | 6.24% | 9.16% | 10.39% | 8.81% | -1.00% | 13.34% | 0.06% | 4.30% | 75.62% |
| 2020 | 6.69% | -4.05% | 4.83% | 6.15% | 0.45% | -1.57% | -2.91% | -0.13% | 6.34% | -6.56% | 2.23% | 1.66% | 12.77% |
| 2019 | 2.11% | 5.80% | 9.89% | -6.57% | -3.32% | 6.29% | -3.14% | 9.69% | -0.04% | 3.89% | 4.20% | 1.43% | 32.92% |
| 2018 | -0.33% | -5.04% | -4.48% | -1.92% | 3.65% | -2.13% | 7.48% | -0.11% | -3.92% | -5.79% | 7.41% | -2.65% | -8.60% |
| 2017 | -2.87% | 0.73% | -1.97% | 10.94% | 5.91% | -0.92% | -3.84% | 12.31% | 1.01% | 5.58% | 1.57% | 3.62% | 35.35% |
| 2016 | -5.00% | -6.29% | 1.55% | 2.17% | 2.45% | -3.68% | 5.86% | -16.71% | -11.93% | -11.98% | -1.82% | 7.02% | -34.55% |
| 2015 | 13.52% | 8.19% | 18.09% | 1.80% | 0.16% | -3.88% | 9.27% | -7.33% | -2.98% | 0.59% | 7.97% | 2.80% | 55.91% |
| 2014 | 10.16% | 17.67% | -2.44% | -1.66% | -4.49% | 8.11% | 2.91% | 0.43% | 8.88% | -4.72% | 1.56% | -4.62% | 33.38% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of NOVO-B.CO is 11, meaning it’s performing worse than 89% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Novo Nordisk A/S (NOVO-B.CO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Novo Nordisk A/S provided a 1.66% dividend yield over the last twelve months, with an annual payout of DKK 9.90 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | DKK 9.90 | DKK 9.90 | DKK 7.08 | DKK 9.83 | DKK 4.68 | DKK 4.30 | DKK 4.08 | DKK 3.93 | DKK 3.80 | DKK 4.70 | DKK 2.50 | DKK 2.25 |
Dividend yield | 1.66% | 1.59% | 1.01% | 2.09% | 1.27% | 2.02% | 2.11% | 2.64% | 2.27% | 3.69% | 1.25% | 1.73% |
Monthly Dividends
The table displays the monthly dividend distributions for Novo Nordisk A/S. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | DKK 0.00 | DKK 0.00 | DKK 0.00 | ||||||||||
| 2024 | DKK 0.00 | DKK 0.00 | DKK 6.40 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 3.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 9.90 |
| 2023 | DKK 0.00 | DKK 0.00 | DKK 4.08 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 3.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 7.08 |
| 2022 | DKK 0.00 | DKK 0.00 | DKK 3.45 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 6.38 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 9.83 |
| 2021 | DKK 0.00 | DKK 0.00 | DKK 2.93 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.75 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 4.68 |
| 2020 | DKK 0.00 | DKK 0.00 | DKK 2.68 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.63 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 4.30 |
| 2019 | DKK 0.00 | DKK 0.00 | DKK 2.58 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 4.08 |
| 2018 | DKK 0.00 | DKK 0.00 | DKK 2.43 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 3.93 |
| 2017 | DKK 0.00 | DKK 0.00 | DKK 2.30 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 3.80 |
| 2016 | DKK 0.00 | DKK 0.00 | DKK 3.20 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 1.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 4.70 |
| 2015 | DKK 0.00 | DKK 0.00 | DKK 2.50 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 2.50 |
| 2014 | DKK 2.25 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 0.00 | DKK 2.25 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Novo Nordisk A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Novo Nordisk A/S was 64.64%, occurring on Jan 4, 1988. Recovery took 774 trading sessions.
The current Novo Nordisk A/S drawdown is 41.87%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -64.64% | Feb 14, 1985 | 718 | Jan 4, 1988 | 774 | Feb 1, 1991 | 1492 |
| -57.03% | Jun 21, 2001 | 275 | Jul 26, 2002 | 912 | Mar 10, 2006 | 1187 |
| -46.16% | Jun 26, 2024 | 144 | Jan 20, 2025 | — | — | — |
| -45% | Apr 1, 1998 | 243 | Mar 22, 1999 | 282 | May 3, 2000 | 525 |
| -44.78% | Aug 6, 2015 | 329 | Nov 23, 2016 | 733 | Oct 30, 2019 | 1062 |
Volatility
Volatility Chart
The current Novo Nordisk A/S volatility is 11.66%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Novo Nordisk A/S compared to its peers in the Biotechnology industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for NOVO-B.CO in comparison to other companies of the Biotechnology industry. Currently, NOVO-B.CO has a PE value of 26.4. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for NOVO-B.CO in comparison to other companies of the Biotechnology industry. Currently, NOVO-B.CO has a PEG value of 1.2. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Novo Nordisk A/S.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |